(PRCT) PROCEPT BioRobotics Corporation Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PRCT) PROCEPT BioRobotics Corporation Complete Analysis Pack
See the Bigger Picture
This PROCEPT BioRobotics Corporation 4P's Marketing Mix Analysis summarizes the company’s Product, Price, Place and Promotion strategy and shows how its surgical robotics offering is positioned and sold; the page includes a real preview/sample of the analysis so you can evaluate style and content before buying—purchase the full version to receive the complete ready-to-use report.
Product
AQUABEAM Robotic System
AQUABEAM Robotic System is PROCEPT BioRobotics Corporation’s core capital product, an image-guided robotic platform that delivers Aquablation therapy for benign prostatic hyperplasia (BPH). BPH affects about 50% of men by age 60 and up to 90% by age 85, so demand is tied to a large, aging patient base. The system supports minimally invasive urologic procedures, which helps hospitals offer an option with strong clinical and workflow appeal.
Aquablation Therapy
Aquablation Therapy is PROCEPT BioRobotics Corporation’s company-built BPH surgery, using a heat-free, robot-guided waterjet to remove prostate tissue and ease lower urinary tract symptoms. It is cleared for men with prostates from 30 to 150 cc, and PROCEPT has said more than 100,000 men have been treated worldwide. In WATER III, 94% of men avoided retreatment at 5 years, supporting its product edge versus older BPH surgery.
HYDROS Robotic System
HYDROS is PROCEPT BioRobotics Corporation’s newer robotic platform, expanding the lineup beyond AQUABEAM and supporting the next phase of robot-assisted BPH care. In 2025-2026, this matters in a U.S. BPH market affecting about 40 million men, giving PROCEPT a larger clinical reach and a stronger product mix for future procedure growth.
Single-Use Consumables
PROCEPT BioRobotics Corporation’s single-use consumables are the recurring disposable parts used in each Aquablation procedure, so revenue grows with procedure volume, not just system sales. This makes every installed capital system a base for repeat purchases. In the latest filings, consumables stayed the key follow-on revenue driver tied to treatment growth.
- Per-procedure recurring revenue
- Tied to Aquablation volume
- Supports installed-base monetization
Clinical Training and Software Support
PROCEPT BioRobotics Corporation backs Aquablation adoption with physician training, proctoring, and clinical support, so hospitals can move faster from evaluation to routine use. Its software and workflow tools help standardize cases and improve OR fit, which supports higher system utilization and repeat adoption.
- Training lowers launch friction.
- Software speeds hospital adoption.
- Support helps drive retention.
PROCEPT’s BPH Platform: Robotics, Recurring Revenue, and Proven Results
PROCEPT BioRobotics Corporation’s Product mix centers on AQUABEAM and HYDROS, with Aquablation Therapy as the core surgery for BPH. The platform serves a large base: about 40 million U.S. men have BPH, and more than 100,000 men have been treated worldwide.
| Product | Key data |
|---|---|
| Aquablation | 30-150 cc; 94% no retreatment at 5 years |
| AQUABEAM/HYDROS | Robotic BPH platforms |
| Consumables | Recurring per procedure |
What is included in the product
Detailed Word Document
Delivers a crisp, company-specific breakdown of PROCEPT BioRobotics Corporation’s Product, Price, Place, and Promotion strategy.
Editable Excel File
Condenses PROCEPT BioRobotics’ 4Ps into a quick, clear snapshot for faster decision-making and easier team alignment.
Reference Sources
Provides a concise, traceable list of primary industry reports, FDA/SEC filings, and benchmark datasets to speed due diligence and validate key assumptions.
Place
Redwood City, California HQ
PROCEPT BioRobotics Corporation is headquartered in Redwood City, California, and that site anchors its corporate, engineering, and commercial leadership. In FY2025, the company reported $258.7 million in revenue, with the Redwood City HQ serving as the main operating base for strategy and execution. The location supports fast decisions across product, sales, and clinical teams.
United States Direct Sales
United States Direct Sales is PROCEPT BioRobotics Corporation’s main market, with U.S. systems and procedure revenue still driving most sales in the latest reported period. The company sells to hospitals and urology centers through direct field teams, not retail, so it can place capital equipment and push adoption faster.
That model fits a high-touch device sell: the team supports trial use, surgeon training, and follow-up, which helps convert capital placements into recurring Aquablation procedures.
Hospitals and Urology Centers
Aquablation therapy is delivered in hospital operating rooms and urology procedure rooms, where surgeons treat benign prostatic hyperplasia (BPH); BPH affects about 50% of men by age 50 and up to 90% by age 80. Access depends on each hospital adopting the system and training physicians, which can slow rollout but supports deeper use once in place. PROCEPT BioRobotics Corporation reported 2025 revenue growth from broader clinical adoption, tied to more hospital and urology center placements.
Select International Markets
PROCEPT BioRobotics Corporation has pushed into select international markets through commercialization outside the U.S., using local distribution partners to reach new hospitals. In 2024, the Company generated over $170 million in revenue, showing that geographic expansion is becoming a real growth driver. This partner-led model lets PROCEPT scale beyond its home market without building a full direct-sales network in every country.
- Uses select market partners abroad
- Supports growth beyond the U.S.
- Backed by $170M+ 2024 revenue
130 Systems Worldwide, 78 U.S. (YE2021)
PROCEPT BioRobotics reported 130 AquaBeam Robotic Systems deployed worldwide at YE2021, with 78 in the United States. That U.S.-weighted base shows where the company’s first commercial traction was strongest, and it matters for service, training, and hospital reference sales.
- 130 systems worldwide at YE2021
- 78 systems in the United States
- U.S. share: about 60%
PROCEPT BioRobotics Expands Through Direct U.S. Hospital Sales
PROCEPT BioRobotics Corporation’s Place strategy is centered on direct U.S. hospital sales, with Redwood City, California as the operating hub. In FY2025, revenue reached $258.7 million, and growth came from more AquaBeam placements and Aquablation use in urology centers. Select international markets add reach through local partners.
| Place factor | FY2025 data |
|---|---|
| HQ | Redwood City, California |
| Revenue | $258.7 million |
| Channel | Direct U.S. sales |
| Global reach | Select partner markets |
Preview Before You Purchase
PROCEPT BioRobotics Corporation Reference Sources
The preview shown here is the actual, full PROCEPT BioRobotics Corporation 4P's Marketing Mix analysis you’ll receive instantly after purchase—no mockups or samples.
Promotion
Clinical Evidence
PROCEPT BioRobotics Corporation leans on clinical proof, not broad brand ads: Aquablation studies have shown durable symptom relief with low retreatment rates, including 2.6% at 5 years in the WATER trial. That matters in physician-led hospital buying, where published outcomes often drive adoption more than price alone. The evidence-first message helps lower perceived risk for surgeons and administrators.
Urology Conferences
PROCEPT BioRobotics Corporation uses urology conferences and medical congresses to reach urologists, surgeons, and hospital buyers where they compare devices and adoption data. These meetings are central in a niche market because buying decisions are driven by clinical evidence and peer review, not broad consumer ads.
At the 2025 AUA and EAU meeting cycle, the company could reinforce Aquablation as a hospital-grade option and support pipeline awareness with live demos and surgeon education. This channel fits a high-cost medtech sales model: one qualified lead can matter more than many low-value impressions.
Physician Training and Proctoring
PROCEPT BioRobotics Corporation uses physician training and proctoring to lower adoption friction, since surgeon education is key to robotic system use. Its hands-on onboarding helps doctors build comfort with new workflows and procedure steps, which supports faster clinical ramp-up. In 2025, that matters as the company kept expanding its installed base and procedure volumes across hospitals.
Key Opinion Leaders
PROCEPT BioRobotics Corporation leans on key opinion leaders, especially physician advocates and clinical experts, to validate Aquablation outcomes in the urology community. This peer backing improves trust and speeds adoption; the company reported 2024 revenue of $243.7 million, up 54% year over year.
- KOLs strengthen clinical credibility.
- Peer-to-peer proof drives adoption.
- 2024 revenue: $243.7 million.
Patient and Provider Education
PROCEPT BioRobotics Corporation’s promotion uses patient and provider education to build BPH awareness, explain symptoms, and show Aquablation benefits and recovery steps. With BPH affecting about 14 million U.S. men, this content helps drive referrals and sharper treatment choices.
- Boosts BPH awareness
- Explains symptoms clearly
- Sets recovery expectations
- Supports referral flow
PROCEPT Wins With Clinical Proof, Not Big Ad Spend
PROCEPT BioRobotics Corporation promotes Aquablation with clinical proof, not mass ads, using outcomes, congresses, and surgeon training to lower adoption risk. In a hospital-led market, peer validation matters most.
Its 2025 AUA and EAU presence, plus proctoring and key opinion leaders, supports surgeon confidence and faster ramp-up. 2024 revenue was $243.7 million, up 54% year over year.
| Promotion lever | Why it matters | Key data |
|---|---|---|
| Clinical evidence | Builds trust | WATER trial 5-year retreatment 2.6% |
| 2025 congresses | Reaches buyers | AUA, EAU |
| Training and KOLs | Speeds adoption | 2024 revenue $243.7M |
Price
Capital Equipment Sale
PROCEPT BioRobotics Corporation sells its AquaBeam platform as a high-value capital system, so hospitals usually buy or finance the robotic unit upfront. Pricing is negotiated deal by deal, not publicly listed, because the sale often includes installation, training, and service terms. This fits a capital-equipment model where the robot is a long-life asset, not a disposable product.
Per-Procedure Consumables
PROCEPT BioRobotics Corporation’s per-procedure consumables price is tied to single-use components sold for each case, so revenue repeats every time an Aquablation procedure runs. That creates a pay-per-procedure model: higher system utilization lifts consumables revenue, while lower case volume slows it. In 2025 filings, this mix stayed central to the company’s recurring-revenue base.
Quote-Based Pricing
PROCEPT BioRobotics Corporation uses quote-based pricing, so it does not publish a standard retail price. Deals are set through direct commercial talks, and the final price can change by customer, contract, and volume. This fits a capital equipment model where system and service terms are negotiated case by case.
Reimbursement-Linked Economics
Aquablation’s price case is stronger because it sits inside established medical reimbursement pathways, so hospitals can bill payers instead of absorbing the full device cost. In 2025, payer coverage still shapes adoption, since urology programs often buy only when reimbursement lowers net patient cost and protects margins. That makes the therapy more accessible and easier to scale across sites.
- Reimbursement reduces hospital buy-in risk.
- Payer coverage drives purchase decisions.
- Access improves when patients face lower out-of-pocket costs.
Service and Support Contracts
PROCEPT BioRobotics Corporation prices its systems with ongoing service, maintenance, and clinical support built in, so customers pay for uptime, adoption, and smoother training, not just the robot itself. That makes the total cost of ownership higher, but it also lowers downtime risk and helps protect utilization across the installed base.
In FY2025, this support model remained tied to recurring revenue quality and customer retention, which matters for a capital device platform with long clinic lifecycles.
- Service supports uptime.
- Clinical help speeds adoption.
- Pricing extends beyond hardware.
- Contracts raise total ownership cost.
PROCEPT’s Quote-Based Model Drives Recurring Revenue Growth
PROCEPT BioRobotics Corporation uses quote-based pricing for AquaBeam, so the robot is sold as a negotiated capital asset, not a posted list-price product. Recurring consumables and service terms then lift lifetime value per hospital, while reimbursement keeps adoption easier for buyers. In FY2025, that mix stayed central to revenue quality.
| Price element | FY2025 takeaway |
|---|---|
| System | Negotiated capital sale |
| Consumables | Per-procedure recurring revenue |
| Service | Bundled support and uptime |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.